Gapping down
In reaction to disappointing earnings/guidance:
- ANET -15.1%, FND -14.6%, SRCL -14.5%, TWI -12%, RBBN -10.5%, EPAY -9.7%, APPN -9.4%, TDC -8.5%, GMED -8%, CTSH -7.7% (after selling off in late trade following the early release of its earnings), LOCO -6.6%, LGND -5.7%, NPTN -5.5%, KLIC -5.4%, BGS -5.2%, FTNT -5.2%, PLNT -5%, ACIA -4.9%, APPF -4.8%, UIS -4.6%, ATVI -4.5%, BL -4.5%, CC -4%, IMGN -4%, HLF -3.8%, MDRX -3.4%, BZH -3.4%, ARCB -3.2%, OEC -3.1%, UPLD -3.1%, GDDY -2.7%, USX -2.7%, EXPE -2.4%, CPSI -2.2%, TRUP -2.1%, SWKS -1.5%, TSLX -1.2%, ITUB -1.2%, D -1.2%, VIRT -1.1%, ATUS -1%, WTR -1%
Other news:
- SRC -3.5% (prices upsized public offering of 10 mln shares of its common stock at a public offering price of $41.00 per share)
- CORT -1.5% (European Medicines Agency recommends orphan drug designation for relacorilant to treat Cushing's Syndrome)
- CHD -1.2% (names CEO Matthew Farrell Chairman of the Board; also downgraded to Sell from Neutral at Citigroup)
- CSCO -1.1% (following ANET earnings/guidance)
- MSON -0.9% (to acquire Solsys Medical)
Analyst comments:
- ACHN -1.7% (downgraded to Underweight from Equal Weight at Barclays)
- EA -1.6% (downgraded to Neutral from Buy at MKM Partners)
- YETI -0.6% (downgraded to Neutral from Buy at Goldman)